PRTN3 and rheumatoid arthritis: Despite similar disease activity, RA male patients had a shorter disease duration (122.6 ± 92.5 vs. 150.3 ± 108.2 months, p = 0.001), received csDMARDs more frequently (77.2% vs. 67.9%, p = 0.014) and were less frequently ACPA-positive (56% vs. 68%, p = 0.003) than their female counterparts.